The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 28 April 2009, www.theannals.com, DOI 10.1345/aph.1G417.
 The Annals of Pharmacotherapy: Vol. 43, No. 5, pp. 928-938. DOI 10.1345/aph.1G417
© 2009 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Charneski, L.
Right arrow Articles by Sym, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Charneski, L.
Right arrow Articles by Sym, D.

NEW DRUG DEVELOPMENTS

Telavancin: A Novel Lipoglycopeptide Antibiotic

Lisa Charneski, PharmD BCPS

Assistant Clinical Professor, Department of Pharmacy Practice and Science, School of Pharmacy, University of Maryland Shady Grove Campus, Rockville, MD

Priti N Patel, PharmD BCPS

Assistant Clinical Professor, Department of Clinical Pharmacy Practice; Director, St. John's University Drug Information Center, St. John's University College of Pharmacy and Allied Health Professions, Queens, NY

Donna Sym, PharmD

Assistant Clinical Professor, Department of Clinical Pharmacy Practice, St. John's University College of Pharmacy and Allied Health Professions; Clinical Preceptor, North Shore University Hospital, Sandra Atlas Bass Campus, Manhasset, NY

Reprints: Dr. Charneski, 9640 Gudelsky Dr., Building 1, Rm. 304, Rockville, MD 20850; fax 301/738-6040, lcharnes{at}rx.umaryland.edu

OBJECTIVE: To review the pharmacology, antimicrobial activity, pharmacokinetics, clinical applications, and safety of telavancin, a new lipoglycopeptide antibiotic.

DATA SOURCES: Literature was obtained from MEDLINE (1966-April 2009) and International Pharmaceutical Abstracts (1971-April 2009) using the search terms telavancin and TD-6424, and also from Theravance, Inc., and Astellas Pharma US, Inc.

STUDY SELECTION AND DATA EXTRACTION: Available English-language articles were reviewed, as well as information obtained from Theravance, Inc., and Astellas Pharma US, Inc.

DATA SYNTHESIS: Telavancin has rapid bactericidal activity against gram-positive aerobic and anaerobic bacteria through multiple mechanisms of action. In vitro and Phase 2 in vivo data support the efficacy of telavancin against antibiotic-resistant gram-positive organisms. On March 4, 2008, the Food and Drug Administration (FDA) accepted as complete for review Theravance's response to the October 19, 2007, New Drug Application approvable letter for telavancin to be used as treatment for complicated skin and skin structure infections (cSSSIs) caused by gram-positive bacteria. QTc interval prolongation has been reported, although the clinical impact of this has not been determined. Drug interactions have not been identified as of yet.

CONCLUSIONS: Telavancin is currently under review by the FDA for the treatment of cSSSIs caused by gram-positive bacteria. The completion of Phase 3 trials will determine whether telavancin will have a role in the treatment of other infections caused by resistant gram-positive bacteria.

Key Words: skin and skin structure infection, telavancin, TD-6424

Published Online, April 28, 2009. www.theannals.com, DOI 10.1345/aph.1G417

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-09-007-H01-P




homecopy help contact us subscription past issues search current issue
Copyright © 2009 by Harvey Whitney Books Company.